Redx Pharma, a UK biotech company, specializes in the discovery and development of novel precision medicines for the treatment of cancer and fibrotic diseases. With a team of around 80 scientists based at their labs in Alderley Park, Cheshire, Redx Pharma leverages their expertise in medicinal chemistry and translational science to discover and develop differentiated therapeutics. They have several product candidates in various stages of development, including a Porcupine inhibitor for oncology, a ROCK2 inhibitor for idiopathic pulmonary fibrosis, and a GI-targeted ROCK inhibitor for fibrostenotic Crohn's disease. Redx Pharma has a strong track record of partnering with global pharmaceutical companies and the NHS, and their work has been endorsed by these collaborations. The company's shares are traded on AIM (AIM:REDX), and they generate revenue from scientific programs, research collaborations, and research and preclinical development services.